Reverse DCF
What growth does the market imply for POLYMED?
Working backwards from the current price to find the FCF growth assumption baked in.
very aggressive
22.0% implied annual FCF growth
The market is pricing in exceptional growth that only a handful of companies sustain for a decade. For context, this company has historically grown at 12.5%. High execution risk.
Current Price
₹1,491
Historical Growth
12.5%
FCF Yield
2.29%
Price / FCF
43.7x
Plain English
To justify today's price of $1491.00, POLYMED.NS needs to grow its free cash flow at 22.0% per year for the next 10 years. That is 9.5% faster than its historical growth rate of 12.5%. At its historical growth rate, the stock cannot justify its current price within a 20-year horizon. The market is pricing in a step-change in performance.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| GDP rate | 10.0% | ₹606 | -59.4% |
| Half implied | 11.0% | ₹654 | -56.1% |
| Historical | 12.5% | ₹734 | -50.8% |
| Implied | 22.0% | ₹1,501 | +0.7% |
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.